Revenue Breakdown
Composition ()
No data
Revenue Streams
Alterity Therapeutics Ltd (ATHE) generates its revenue primarily from Reaserch and development in the field of Paekinsonaian movement disorders, which accounts for 100.0% of total sales, equivalent to $10.89K. Understanding this concentration is critical for investors evaluating how ATHE navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Alterity Therapeutics Ltd maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -7817.78%, while the net margin is -6445.10%. These profitability ratios, combined with a Return on Equity (ROE) of -154.88%, provide a clear picture of how effectively ATHE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ATHE competes directly with industry leaders such as ACTU and VRCA. With a market capitalization of $62.53M, it holds a significant position in the sector. When comparing efficiency, ATHE's gross margin of 100.00% stands against ACTU's N/A and VRCA's 92.27%. Such benchmarking helps identify whether Alterity Therapeutics Ltd is trading at a premium or discount relative to its financial performance.
